Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 2013

View Archived Issues

The Korea Institute of Ocean Science and Technology synthesizes novel agents for cancer

Vertex Pharmaceuticals discloses new agents for influenza

New agents that inhibit AIMP2-DX2 selected by Korean researchers

XOMA-3AB well tolerated in phase I study

Tulane University researchers describe B. pseudomallei vaccine strategy

Takeda Pharmaceutical synthesizes new inhibitors of ROR gamma t

Dainippon Sumitomo Pharma divulges new neutrophil elastase inhibitors

Pooled phase Ib results for dupilumab show efficacy in atopic dermatitis

Second phase III trial of tavaborole in onychomycosis meets endpoints

Cubist Pharmaceuticals obtains QIDP and fast track designations for late-stage antibiotic candidates

FluoroPharma Medical reports data from phase II CardioPET study

Kythera Biopharmaceuticals presents phase III results for ATX-101

Adventrx Pharmaceuticals to change name, provides update on ANX-188

BioAlliance Pharma signs agreement with global vaccine company

Progen signs licensing agreement for PG-545

Pseudomonas-specific antibiotic POL-7080 completes phase I study

Novo Nordisk launches new long-acting insulin Tresiba in Denmark

Santhera considering strategic options following decisions regarding Catena and Raxone

NeuroDerm completes phase I study of levodopa/carbidopa patch pump

Enrollment completed in phase II study of PsiOxus' MT-102 for cancer cachexia

FDA approves revised SPA for phase III trial of Collategene in critical limb ischemia

FDA approves expanded indication for Corifact

miRNAs as novel targets in androgen-independent prostate cancer

UCLA receives funding to identify genetic changes that affect the severity of DMD

Companies partner to advance allosteric modulators targeting adenosine A2A receptor

Alere receives Gates Foundation grant to develop tuberculosis assay

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...